The effectiveness of genetic engineering with lentivectors to protect transplanted cells from allogeneic rejection was examined using, as a model, type 1 diabetes treatment with b-cell transplantation, whose widespread use has been limited by the requirement for sustained immunosuppressive treatment to prevent graft rejection. We examined whether lentivectors expressing select immunosuppressive proteins encoded by the adenoviral genome early region 3 (AdE3) would protect transplanted b-cells from an alloimmune attack. The insulinproducing b-cell line bTC-tet (C3HeB/FeJ-derived) was transduced with lentiviruses encoding the AdE3 proteins gp19K and RIDa/b. The efficiency of lentiviral transduction of bTC-tet cells exceeded 85%. Lentivector expression of gp19K decreased surface class I major histocompatibility complex expression by over 90%, whereas RIDa/b expression inhibited cytokineinduced Fas upregulation by over 75%. bTC-tet cells transduced with gp19K and RIDa/b lentivectors, but not with a control lentivector, provided prolonged correction of hyperglycemia after transplantation into diabetic BALB/c severe combined immunodeficient mice reconstituted with allogeneic immune effector cells or into diabetic allogeneic BALB/c mice. Thus, genetic engineering of b-cells using gp19K-and RIDa/bexpressing lentiviral vectors may provide an alternative that has the potential to eliminate or reduce treatment with the potent immunosuppressive agents necessary at present for prolonged engraftment with transplanted islets.
Introduction
Genetic engineering using lentiviral vectors is a powerful technique that permits modification of cells to express defined genes, either to correct a genetic deficiency or to alter cellular function and in vivo biological behavior. Transplantation of a variety of cell types is at present being explored as a modality to treat several diseases caused by the absence or destruction of functionally critical cell populations. 1 For example, type 1 diabetes is an autoimmune disease characterized by the loss of the insulin-producing b-cells present in the pancreatic islets, resulting in sustained hyperglycemia and subsequent damage to multiple organs. Although lifelong daily injections of insulin provide an effective palliative therapy for the disease, they do not constitute a cure. The need for chronic insulin therapy could be obviated by pancreatic islet transplantation, but less than 10% of patients remain insulin independent 5 years after this procedure, 2 owing to alloimmune and autoimmune responses that develop despite treatment with potent immunosuppressive drugs 3 and to the deleterious effects of the immunosuppressive agents on b-cell maintenance and function. 4 Furthermore, the chronic immunosuppressive therapy required to allow sustained engraftment after transplantation of any allogeneic cell population increases the susceptibility of patients to infections and malignancies, and each drug has specific adverse side effects (for example, nephrotoxicity) that may necessitate discontinuation. 2, 5 An alternative to chronic immunosuppressive therapy for transplant recipients would be to transplant cells that have been genetically modified to protect them from detection and/or elimination by the immune system of the recipient. To explore the efficacy of this approach, we hypothesized that we could examine the capacity of genetic engineering to protect transplanted cells from rejection by genetically engineering b-cells to express selected immunosuppressive adenoviral (Ad) proteins, encoded in early region 3 (E3) of the viral genome. The E3 region encodes seven proteins, several of which inhibit the capacity of the immune system to recognize and eliminate infected cells and thereby protect Ad-infected cells from clearance by the host. 6 For example, the AdE3-encoded RID (Receptor Internalization and Degradation) complex, composed of a and b subunits, inhibits apoptosis induced by tumor necrosis factor (TNF)-a, and other members of the TNF family, such as Fas and TNF-related apoptosis-inducing ligand, [7] [8] [9] blocks TNF-a-induced nuclear factor-kB activation of proinflammatory genes, 10 and suppresses the synthesis of chemokines. 11 Another AdE3-encoded protein, gp19K, inhibits the surface expression of class I major histocompatibility complex (MHC) molecules, thereby preventing the infected cells from presenting Ad-derived peptides on their surface, thus forestalling their resultant elimination by Ad-specific CD8 + cytotoxic T lymphocytes. 12 Some of the immune pathways inhibited by the AdE3 proteins to prevent elimination of Ad-infected cells have also been implicated in the rejection of allogeneic transplanted islets 13, 14 as well as the autoimmune-mediated etiology of type 1 diabetes. 15, 16 Islet cells from mice transgenic for the expression of the entire AdE3 region under the control of the rat insulin II promoter were protected from allograft rejection 17 and b-cell-specific autoimmunity. [18] [19] [20] These studies using transgenic mice suggested that the expression of all of the AdE3 genes by b-cells could facilitate their transplantation across allogeneic barriers, without a requirement for continued systemic immunosuppression, and could also inhibit autoimmune destruction of b-cells. However, transgenic modification of human islets before transplantation to express all seven proteins encoded by the AdE3 region for clinical use is not feasible. Furthermore, given the shortage of human islets and the focus on generating reproducible, transplantable cell lines for transplantation in type 1 diabetes as opposed to whole islets, we utilized the clinically feasible approach of using lentiviral vectors to determine whether expression of only three proteins, RIDa, RIDb and gp19K, would be sufficient to protect islet cells from allogeneic rejection. Human T cells modified ex vivo by lentiviral vectors were shown recently to be safe in a phase I clinical trial for human immunodeficiency virus-1 gene therapy. 21 No adverse events or instances of insertional mutagenesis were reported after up to 3 years of follow-up, suggesting the potential clinical feasibility of lentiviral-mediated gene transfer for treatment of other diseases, including type 1 diabetes. In this report, we demonstrate that lentiviral vectors can be used to engineer the insulin-secreting murine b-cell line bTC-tet 22, 23 to express three AdE3 proteins, RIDa, RIDb and gp19K. We overcame the requirement for coordinated expression of the RID a and b subunits for functional activity of the RID complex by expressing both together using a single lentiviral vector engineered to express RIDa and RIDb linked with a 'self-cleaving' picornavirus 2A peptide that enables the stoichiometric production of two proteins from a single transcript. 24 We report that bTC-tet cells genetically engineered to express RIDa/b and gp19K by lentiviral transduction provided prolonged correction of hyperglycemia after transplantation into diabetic severe combined immunodeficient (SCID) mice reconstituted with allogeneic immune effector cells or into diabetic allogeneic BALB/c mice.
Results

Development of a mouse model to study allogeneic rejection of islet cells
To study the capacity of lentiviral vectors to genetically engineer cells to resist allogeneic rejection, we used a model of transplantation-mediated treatment of type 1 diabetes utilizing a conditionally immortalized, insulin-producing b-cell line bTC-tet derived from a mouse insulinoma. 22, 23 Insulin production by bTC-tet cells is regulated in a glucosedependent manner permitting these cells to maintain physiologically normal serum glucose levels in vivo.
23
Proliferation of the bTC-tet cells is induced by expression of a stably integrated simian virus 40 (SV40) large tumor antigen (TAg) that is negatively regulated by tetracycline. 22, 23 This permits reversible arrest of the in vivo growth of the bTC-tet cells after transplantation into mice by adding doxycycline to the drinking water of the recipient mouse. As reported previously, 22 transplantation of the bTC-tet cells into syngeneic C3HeB/FeJ mice made diabetic by STZ treatment corrected hyperglycemia and mediated prolonged normoglycemia ( Figure 1a ). In contrast, bTC-tet cells transplanted into diabetic allogeneic BALB/c mice had no significant effect on hyperglycemia, most likely a result of immune rejection of the transplanted cells (Figure 1b) . To study the capacity of genetic engineering using lentiviral vectors expressing immmunoinhibitory genes to protect transplanted bTC-tet cells from rejection, we developed a model using BALB/c SCID mice. The immunodeficient state of these mice allowed transplantation of the bTC-tet cells into these tolerant mice whose immune system could be selectively reconstituted by adoptively transferring splenocytes from allogeneic mice. After BALB/c SCID mice were rendered diabetic by treatment with STZ, the mice were transplanted by intraperitoneal injection with bTC-tet cells. By 3-4 weeks after transplantation, the SCID mice normalized their blood glucose levels (Figure 1c ). When the blood glucose in the transplanted mice normalized to between 100 and 150 mg per 100 ml, doxycycline was added to the drinking water to halt proliferation of bTC-tet cells and prevent hypoglycemia.
We next examined whether the islet cells transplanted into diabetic SCID mice would be rejected by adoptively transferred allogeneic leukocytes as indicated by the subsequent recurrence of hyperglycemia. Several days after normalization of the blood glucose, splenocytes obtained from C3HeB/FeJ mice (syngeneic with the bTCtet cells), unprimed allogeneic BALB/c mice or BALB/c mice primed by immunization with C3HeB/FeJ splenocytes were injected intravenously (i.v.) into the mice. After the mice were injected with C3HeB/FeJ splenocytes, the blood glucose values remained at normoglycemic levels (o180 mg per 100 ml) for the duration of the experiment (Figure 2a ). In contrast, hyperglycemia recurred in BALB/c SCID mice after adoptive transfer with allogeneic splenocytes (Figure 2b ). Whereas recurrence of hyperglycemia occurred about 25 days after the mice were injected with unprimed allogeneic splenocytes, hyperglycemia recurred in almost half the time in mice injected with splenocytes from BALB/c mice primed with C3HeB/FeJ splenocytes (Figure 2b ). The accelerated onset of hyperglycemia when the transferred allogeneic splenocytes were isolated from primed mice indicated that the recurrence of hyperglycemia was due to immune-mediated depletion of the bTC-tet cells.
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These results validated the use of this model to test the capacity of lentiviral vectors to protect bTC-tet cells from immune-mediated rejection.
Lentiviral vectors efficiently introduce AdE3 genes into bTC-tet cells
We next examined whether expression of three genes from the AdE3 complex using third-generation lentiviral vectors, which efficiently transduce a wide range of cells and enable prolonged gene expression in the transduced cells and their progeny, 25 would be sufficient to prevent immune-mediated rejection of the bTC-tet cells. Adenoviruses extensively splice E3 transcripts to express the individual E3 proteins. As lentiviruses lack the capacity to recapitulate this process, we constructed separate lentivectors expressing selected E3 proteins, specifically gp19K and RIDa/b. The RID complex is comprised of a 10.4 kDa a-chain and a 14.5 Kd b-chain, and its functional activity requires both chains. To express both proteins using a single lentiviral vector and promoter, we linked the genes encoding the RIDa and RIDb chains with a sequence encoding a 'self-cleaving' picornavirus 2A peptide that enables the stoichiometric production of two proteins from a single transcript. Genetic engineering to prevent rejection T Kojaoghlanian et al H-2K k was reduced by over 90% in bTC-tet cells transduced with the gp19K lentivirus, but was unchanged in bTC-tet cells transduced with the RIDa-2A-RIDb lentivector (Figure 4a ). The capacity of the gp19K lentivector to downregulate MHC expression was only marginally affected by co-transduction of the bTC-tet cells with the RIDa-2A-RIDb lentivector. To evaluate efficient translation, cleavage and function of the lentivector-encoded RIDa-2A-RIDb protein, we examined the capacity of the RIDa-2A-RIDb-encoding lentiviral vector to block IL (interleukin)-1b/TNF-astimulated surface expression of Fas, a member of the TNF superfamily that is a major mediator of T-cell killing and is involved in the allogeneic rejection and apoptosis of b-cells. 26 Transduction of bTC-tet cells with the RIDa-2A-RIDb-encoding lentiviral vector reduced by over 75% the cytokine-induced surface expression of Fas as compared with IL-1b/TNF-a-treated bTC-tet cells transduced with a control lentivector (Figure 4b ). Thus, taken together, these results indicate that lentiviral vectors efficiently transduce bTC-tet cells and mediate expression of functional gp19K and RIDa/b proteins that exert their immunosuppressive effects. 
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Transduction with gp19K and RIDa/b lentivectors before transplantation protects bTC-tet cells from rejection by allogeneic immune effector cells
After hyperglycemia was induced in SCID mice by injection with STZ, the mice were injected with bTC-tet cells that were either cotransduced with lentivectors encoding gp19K and RIDa-2A-RIDb or transduced with a control vector. After normalization of blood glucose, the mice were injected i.v. with primed BALB/c splenocytes. All of the mice injected with bTC-tet cells transduced with the control lentivector developed recurrence of hyperglycemia within 2-3 weeks after injection of primed splenocytes (Figure 5a ). In contrast, despite injection with primed allogeneic splenocytes, six out of the eight mice injected with bTC-tet cells transduced with the gp19K and RIDa-2A-RIDb lentivectors remained diabetes free for up to 5 months posttransplant (Figure 5b ). These results indicated that lentiviral vectors efficiently engineered bTC-tet cells to express gp19K, RIDa and RIDb and protected transplanted cells from allogeneic rejection by the transferred primed BALB/c leukocytes.
Lentiviral-mediated expression of gp19K and RIDa/b prolongs the ability of bTC-tet cells to correct hyperglycemia in diabetic allogeneic BALB/c mice We examined whether lentiviral vector-mediated expression of gp19K, RIDa and RIDb could protect bTC-tet cells from rejection after transplantation into an allogeneic host. After BALB/c mice were rendered diabetic with STZ, they were injected with bTC-tet cells that were either cotransduced with lentivectors encoding gp19K and RIDa-2A-RIDb or transduced with a control lentivector. bTC-tet cells transduced with the control lentivector did not significantly alter the hyperglycemia in the mice (Figure 6a 
Discussion
Genetic engineering using lentiviral vectors enables the engineering of cells to decrease their susceptibility to Figure 5 Lentivector transduction with gp19K and RIDa/b prolongs control of hyperglycemia by transplanted bTC-tet cells in SCID mice after adoptive transfer of primed allogeneic splenocytes. bTC-tet cells were transduced with either (a) a control lentivector or (b) the lentivectors expressing gp19K and RIDa/b, and 4 days later, the bTC-tet cells (6 Â 10 6 cells per mouse) were injected i.p. into diabetic BALB/c SCID mice (week 1). When normoglycemia was achieved, splenocytes from primed BALB/c mice (3 Â 10 7 cells) were injected i.v. In (b), six of the eight SCID mice transplanted with the AdE3-expressing cells maintained normoglycemia for over 20 weeks after splenocyte transfer (solid lines), whereas two mice became hyperglycemic within 4 weeks (broken lines). In (a) and (b), the horizontal line indicates a blood glucose value of 300 mg per 100 ml. Figure 6 bTC-tet cells transduced with gp19k and RIDa/b lentivectors, but not with a control lentivector, correct hyperglycemia after transplant into diabetic BALB/c mice. bTC-tet cells were transduced with either (a) a control lentivector or with (b) gp19K and RIDa/b lentivectors. After 4 days, the bTC-tet cells (7 Â 10 6 cells per mouse) were injected i.p. into diabetic allogeneic BALB/c mice (week 1) and blood glucose was monitored. In (b), five of the six mice attained normoglycemia after transfer (solid lines), whereas only one did not (broken line). In (a) and (b), the horizontal line indicates a blood glucose value of 300 mg per 100 ml.
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T Kojaoghlanian et al allogeneic rejection after transplantation. Cellular transplantation of a variety of cell types (including hepatocytes, myoblasts, endothelial cells, neural cells and chondrocytes) is being explored as a potential therapeutic strategy for a number of disease states. 1 Ex vivo genetic engineering of these cell types with lentiviral vectors encoding immunoprotective proteins could be used as a strategy to improve survival of grafts transplanted across allogeneic barriers. We tested the physiological implementation of this approach using a model of treating diabetes with transplanted insulinproducing b-cells. After islet transplantation into patients with type 1 diabetes, b-cells are subject to elimination by both alloimmune and autoimmune responses, 3 necessitating the administration of potent immunosuppressive drug regimens having serious side effects. 2, 5 The application of genetic engineering to modify b-cells ex vivo before transplantation and protect them from immune destruction represents an attractive alternative approach that is being explored in multiple laboratories. [27] [28] [29] [30] [31] [32] Here, we demonstrate that lentiviral vector expression of three AdE3 proteins (gp19K, RIDa and RIDb) is sufficient to prevent b-cell allograft rejection and permit prolonged correction of hyperglycemia without the requirement for systemic immunosuppression. Lentiviral vectormediated expression of gp19K, RIDa and RIDb by bcells protects them from elimination by the immune system most likely by decreasing expression of class I MHC molecules and inhibiting cytokine-induced Fas upregulation (Figure 4 ). AdE3 gp19K inhibits class I MHC-mediated antigen presentation by binding the MHC heavy chain and retaining it in a nonfunctional form in the endoplasmic reticulum. 12 It is unlikely that lentiviral vector reduction of class I MHC expression to prevent cytotoxic T lymphocyte killing will be sufficient to protect b-cells from immune rejection because of the reported important role of CD4 + T cells as well as innate immunity in islet allorejection. 33 For this reason, we engineered a lentiviral vector capable of expressing RIDa and RIDb, in addition to gp19K, in the bTC-tet cells. The RIDab complex has been shown to inhibit Fas ligandinduced cell death by downregulating Fas from the cell surface through a mechanism that involves Fas internalization and targeted degradation in the lysosome. 34 Lentiviral vector-mediated coexpression of gp19K and that of RIDa and RIDb were sufficient to protect transplanted bTC-tet cells from alloimmune destruction in most, but not all, recipients (Figures 5b and 6b) . Our ability to use third-generation lentivectors and a 2A linker to efficiently transduce b-cells and express multiple proteins by a single vector will allow us to explore the possibility of adding other immunomodulatory proteins to our system. The lentiviral system provides the advantage of very high efficiency of transduction and stable integration with continued expression of the protective gene for prolonged periods of time without the limitations of vector toxicity. 27, 35 The model system we used for this study, diabetic SCID mice whose hyperglycemia is corrected by transplanted bTC-tet cells until they are rejected by transferred allogeneic leukocytes, provides a high-throughput model for studying the in vivo impact of lentiviral vectormediated genetic engineering to protect b-cells from immune-mediated rejection, as well as for investigating the in vivo immune mechanisms of rejection. A major strength of the lentiviral vector system is that it can be extended in an iterative process to delineate the immune response genes critical for the triggering of immunemediated rejection of b-cells. The use of lentiviral vectors encoding siRNA constructs would enhance their capacity to inhibit specifically a range of immune response genes in the transplanted b-cells and permit us to examine the impact of downregulating these genes on conferring resistance to b-cell rejection after adoptive transfer of the transplanted SCID mice with defined populations of allogeneic leukocytes. Alternatively, we could also examine the effect of lentiviral vectormediated overexpression of molecules such as PD-L1, 36 which would deliver inhibitory signals to T cells and thereby protect transplanted cells from rejection. Such experiments would not only help in the definition of the molecular and cellular participants in b-cell rejection, but they might also suggest alternatives or adjunct genes to gp19K, RIDa and RIDb for the lentiviral vector-mediated protection of transplanted b cells.
Although we have shown that expression of gp19 K, RIDa and RIDb can protect transplanted b-cells from alloimmune destruction, clinical translation to patients with type 1 diabetes will require that the lentiviral vector-encoded genes also protect the cells from autoimmune responses. Non-obese diabetic mouse studies demonstrated that transgenic expression of the entire AdE3 region by b-cells could indeed protect them from autoimmune attack. 19, 20 However, in mice transgenic for the expression of gp19K alone, or of a combination of RIDa/b and another adenoviral protein 14.7 K, each conferred less protection from autoimmune destruction of islets than did expression of the entire E3 region. 19 Whether lentiviral vector-mediated coexpression of gp19K and RIDa/b will be sufficient to protect b-cells from autoimmune attack remains to be determined. We will also need to explore whether an immune response will be generated against the lentiviral vector-delivered gp19K, RIDa and RIDb themselves, which could lead to the undesired elimination of the lentiviral-vector transduced b-cells. However, we are encouraged by the report that inclusion of the AdE3 complex in an Ad-based gene therapy vector resulted in the inhibition of cytotoxic activity against Ad-infected cells, as well as a diminished humoral response to viral proteins. 37 A further challenge is indicated by our finding that allogeneic recipients of AdE3-expressing bTC-tet cells experience a recurrence of their diabetes at 10 weeks post-transplant (Figure 6b) . One explanation for these findings is that the expression of the AdE3 proteins declines over time, and so the bTC-tet cells eventually become vulnerable to immune rejection. An alternative explanation is that expression of gp19K and RIDa/b in combination is simply insufficient to protect bTC-tet cells indefinitely from alloimmune rejection. Unfortunately, it is not possible to discriminate between these two explanations experimentally in our system, as cells injected into the peritoneal cavity cannot be quantitatively recovered. Furthermore, it is, of course, not possible to measure the E3 expression of cells that have already been eliminated. Alternative systems will need to be devised to investigate these important issues. Further investigation will also need to address the finding that transplantation of transduced bTC-tet cells did not reverse diabetes in all recipients in the presence Genetic engineering to prevent rejection T Kojaoghlanian et al of transferred or endogenous allogeneic leukocytes (Figures 5b and 6b) . All of the animals shown in Figure  5b received the same batch of transduced bTC-tet cells, as did all of the recipients in Figure 6b . Thus, within each experiment, all should have received comparable numbers of cells expressing the AdE3 proteins and at comparable levels. It is possible, however, that AdE3 expression levels were altered in vivo such that they varied from one recipient to another. For the technical reasons just described, we could not determine whether the ineffectiveness of a transplant correlated with reduced expression of the AdE3 proteins in vivo in individual recipients. The variability in clinical response may reflect instead, or in addition, variable immune function from one recipient to another.
The shortage of human islet donors is one of our motivations for examining the capacity of lentiviral vectors to genetically engineer isolated b-cells rather than intact islets. Our long-term goal is to use lentiviral vectors to engineer b-cells capable of producing insulin in a glucose-regulated manner that can be transplanted into diabetic individuals and correct hyperglycemia without requiring treatment with immunosuppressive agents. The murine bTC-tet cell line is well differentiated, has a stable phenotype and maintains the normal regulation of insulin secretion in both growth-arrested and growing cells. 22, 23 However, concerns associated with xenotransplantation 38 make it unlikely that these lentiviral vector-encoded murine cells will be used to treat humans. As reviewed, 39 to obtain human b-cells for transplantation into patients, multiple groups are attempting to produce b-cells from embryonic stem cells or from stem/progenitor cells isolated from human fetal liver, adult pancreas or other adult organs. Encouraging results have been obtained from at least some of these approaches. 40, 41 Once a reliable source of human b-cells becomes available, our findings suggest that lentiviral vectors can be used to genetically engineer b cells to express gp19K, RIDa and RIDb before transplantation and eliminate or markedly reduce the requirement for potent immunosuppressive regimens. This approach can be applied readily to protect any transplanted cell population from allogeneic rejection, thereby reducing the need for the immunosuppressive agents necessary at present for transplantation protocols, and it would greatly expand the application of cellular transplantation as a therapeutic approach.
Materials and methods
Cell lines and animals
bTC-tet cells, derived from C3HeB/FeJ mice (H-2 k ) and described previously, 22, 23 were maintained in Dulbecco's modified Eagle's medium (DMEM; 4.5 g per liter of glucose) containing 10% fetal bovine serum, 100 U ml À1 penicillin and 100 mg ml À1 streptomycin. The 293T cells used for generation of the lentivectors were maintained in Iscove's modified Dulbecco's medium with 10% fetal bovine serum, 10 mM HEPES, 10 mM glutamine, 100 U ml À1 penicillin and 100 mg ml 
Transplantation protocol
Female mice 8-10 weeks of age were injected with 200 mg kg À1 streptozotocin (STZ) intraperitoneally (i.p.). Blood glucose was monitored (One Touch Ultra; offscale readings are reported as 600 mg per 100 ml) until the animals became diabetic (4300 mg per 100 ml on two separate occasions). bTC-tet cells were trypsinized, washed and resuspended in PBS, and then injected i.p. into diabetic mice. When blood glucose reached 100-150 mg per 100 ml, doxycycline (2 mg ml
À1
) was added to the drinking water to arrest the growth of the transplanted cells.
Priming of immune effectors and adoptive transfer of splenocytes
For priming, splenocytes from C3HeB/FeJ mice were isolated, purified by density centrifugation over Ficoll and 2 Â 10 7 splenocytes were injected subcutaneously into immunocompetent BALB/c mice. After 2-3 weeks, splenocytes from primed mice were purified and injected i.v. into transplanted SCID mice (3 Â 10 7 cells per mouse) and blood glucose was monitored weekly.
Generation and production of lentiviral vectors
Vesicular stomatitis virus glycoprotein (VSV-G) pseudotyped, human immunodeficiency virus-1-based, thirdgeneration lentiviruses, 25 one expressing gp19K, amplified by PCR from Ad2E3/pcDNA3, 37 and the other expressing the RIDa and RIDb genes, amplified by PCR from Ad2 RIDa/pcDNA3 and Ad2 RIDb/pcDNA3 plasmids, respectively, and linked with a 2A peptide (RIDa-2A-RIDb), 24 were generated by calcium phosphate-mediated cotransfection of 293T cells with four plasmids: a CMV promoter-driven packaging construct expressing the gag and pol genes, an RSV promoterdriven construct expressing rev, a CMV promoter-driven construct expressing the VSV-G envelope and a selfinactivating transfer construct driven by the hPGK promoter containing the human immunodeficiency virus-1 cis-acting sequences and an expression cassette for either gp19K or the RIDa-2A-RIDb coding sequence inserted upstream of an IRES-regulated GFP. 24 Control (GFP only) lentivirus was generated by transfecting 293T cells expanded in 10 cm tissue culture plates with the packaging, Rev-expressing, Env-expressing and the basal expression constructs in the presence of calcium phosphate. The culture media was replaced 12-16 h after transfection, and the supernatant was collected, filtered and concentrated by ultracentrifugation (50 000 g for 2.5 h) 24 and 48 h later. The viral pellet was resuspended in sterile PBS and frozen in aliquots at À80 1C until use. The concentration of the lentiviruses was determined by measurement of p24 in the supernatant by ELISA. The bTC-tet cells were transduced by lentivectors as described. 42 Briefly, the bTC-tet cells were resuspended in 0.5 ml of complete Iscove's modified Dulbecco's medium with added polybrene (4 mg ml
À1
) and plated into Genetic engineering to prevent rejection T Kojaoghlanian et al 24-well plates (1 Â 10 5 cells per well). The indicated lentiviral vector (100 ng of p24) was added to each well, the plates were centrifuged (2500 r.p.m. for 1 h) and incubated overnight at 37 1C. The next day, complete Iscove's modified Dulbecco's medium was added to each well and incubated for an additional 5 days. Transduction efficiency and gene expression were determined by flow cytometry as described below.
Flow cytometry
Flow cytometry was performed with an LSRII (BD Biosciences, San Jose, CA, USA), and FlowJo software (Treestar, Ashland, OR, USA) was utilized for data analysis. bTC-tet cells were stained with an antibody to H-2K k class I MHC (CTKk; Serotec) or with an antibody to mouse Fas (Jo2; BD Biosciences). For the latter, the cells were stimulated with mTNF-a (100 ng ml
À1
) and mIL-1b (10 ng ml À1 ) overnight before harvesting and staining. Subsequent staining steps were performed on ice. Pellets were washed twice in 0.5% bovine serum albumin in PBS and incubated in fluorescence-activated cell sorting buffer (2% fetal bovine serum in PBS) for 10 min on ice. Cells were pelleted and resuspended in 100 ml of fluorescence-activated cell sorting buffer with specific antibody or the corresponding isotype control and incubated for 30-45 min. Cells were washed twice in fluorescence-activated cell sorting buffer then fixed with 2% paraformaldehyde in PBS before analysis. Cells were then analyzed for GFP and phycoerythrin by gating on the viable bTC-tet cell population by forward and side scatter and then compensating using FlowJo software.
Reverse transcriptase PCR
bTC-tet cells were infected with the indicated lentivectors for 5 days and total RNA was isolated using Trizol reagent and quantitated by optical density at 260 nm. After treatment with RNAse-free DNAse, RNA was reverse-transcribed and amplified using the OneStep reverse transcriptase PCR kit (Qiagen, Valencia, CA, USA) following the manufacturer's protocol. The primer pairs for mRNA transcript detection used were 5
0 -CTAT TTGGCAGCCAGGTGACACTA-3 0 and 5 0 -GCTGTAATA AGCAGAGCGGTGGAA-3 0 (202 bp product), 5 0 -CATCA TGGATCCCATGATTCCTCGAGTTC-3 0 and 5 0 -CACAGT CGACTTAAAGAATTCTGAG-3 0 (275 bp product), 5 0 -CA TCATGGATCCCATGAAACGGAGTGTC-3 0 and 5 0 -CAC AGTCGACTCAGTCATCTCCACCTG-3 0 (392 bp product) for gp19K, RIDa and RIDb transcripts, respectively. A mouse actin primer pair (5 0 -TCGTACCACAGGCAT TGTGATGGA-3 0 and 5 0 -TGATGTCACGCACGATTTCC CTCT-3 0 ) (199 bp product) was used to confirm mRNA integrity. The amplified products were detected by size fractionation on an ethidium bromide-stained gel.
Assessment of insulin content of bTC-tet cells
Four to six days after plating cells in 12-well culture dishes (5 Â 10 5 cells per well), the cells were washed twice with PBS and 1 ml of 3 M acetic acid was added to each well. The cells were harvested, sonicated twice for 20 s, centrifuged at 1000 g and the supernatant was lyophilized and reconstituted in 0.1% bovine serum albumin in PBS. Insulin levels were determined using an insulin-specific RIA. 43 
